ESPR

Esperion Therapeutics, Inc.

2.90 USD
+0.01 (+0.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Esperion Therapeutics, Inc. stock is up 33.03% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 11 June’s closed higher than May. In the last 9 Unusual Options Trades, there were 5 PUTs, 4 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
18 Apr 14:25 19 Apr, 2024 2.50 PUT 1000 1045
18 Apr 19:24 17 Jan, 2025 3.00 PUT 200 3229
19 Apr 15:53 17 May, 2024 2.50 PUT 1000 1393
06 May 19:57 17 Jan, 2025 2.00 CALL 410 21758
07 May 13:32 21 Jun, 2024 3.00 PUT 555 709
22 May 17:06 17 Jan, 2025 2.00 PUT 500 1703
22 May 19:27 17 Jan, 2025 3.00 CALL 433 4507
10 Jun 13:47 19 Jul, 2024 3.00 CALL 1000 7212
12 Jun 15:48 20 Sep, 2024 3.00 CALL 700 2692

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.

  • HC Wainwright & Co.
    Wed May 22, 11:58
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 21, 05:41
    buy
    confirm